Bernd Clement

Kiel, SH 24118, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 61 publications

Dual Topoisomerase Inhibitor Is Highly Potent and Improves Antitumor Response to Radiotherapy in Cervical Carcinoma.

Dual Topoisomerase Inhibitor Is Highly Potent and Improves Antitumor Response to Radiotherapy in Cervical Carcinoma.

Journal: International journal of molecular sciences

Published: January 31, 2025

Scientific basics of pharmacist education

Scientific basics of pharmacist education

Journal: Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz

Published: December 03, 2024

mARC1 Is the Main Contributor to Metabolic Reduction of N-Hydroxyurea.

mARC1 Is the Main Contributor to Metabolic Reduction of N-Hydroxyurea.

Journal: Journal of medicinal chemistry

Published: October 14, 2024

In Vivo and In Vitro Pharmacokinetic Studies of a Dual Topoisomerase I/II Inhibitor.

In Vivo and In Vitro Pharmacokinetic Studies of a Dual Topoisomerase I/II Inhibitor.

Journal: ACS pharmacology & translational science

Published: October 11, 2024

Second-Coordination-Sphere Effects Reveal Electronic Structure Differences between the Mitochondrial Amidoxime Reducing Component and Sulfite Oxidase.

Second-Coordination-Sphere Effects Reveal Electronic Structure Differences between the Mitochondrial Amidoxime Reducing Component and Sulfite Oxidase.

Journal: Inorganic chemistry

Published: October 01, 2024

mARC1 in MASLD: Modulation of lipid accumulation in human hepatocytes and adipocytes.

mARC1 in MASLD: Modulation of lipid accumulation in human hepatocytes and adipocytes.

Journal: Hepatology communications

Published: September 15, 2023

Reduction of Hydrogen Peroxide by Human Mitochondrial Amidoxime Reducing Component Enzymes.

Reduction of Hydrogen Peroxide by Human Mitochondrial Amidoxime Reducing Component Enzymes.

Journal: Molecules (Basel, Switzerland)

Published: August 01, 2023

The mitochondrial amidoxime reducing component-from prodrug-activation mechanism to drug-metabolizing enzyme and onward to drug target.

The mitochondrial amidoxime reducing component-from prodrug-activation mechanism to drug-metabolizing enzyme and onward to drug target.

Journal: The Journal of biological chemistry

Published: June 19, 2023

The History of mARC.

The History of mARC.

Journal: Molecules (Basel, Switzerland)

Published: May 12, 2023

Active Site Structures of the Escherichia coli N-Hydroxylaminopurine Resistance Molybdoenzyme YcbX.

Active Site Structures of the Escherichia coli N-Hydroxylaminopurine Resistance Molybdoenzyme YcbX.

Journal: Inorganic chemistry

Published: March 27, 2023

Combined PARP and Dual Topoisomerase Inhibition Potentiates Genome Instability and Cell Death in Ovarian Cancer.

Combined PARP and Dual Topoisomerase Inhibition Potentiates Genome Instability and Cell Death in Ovarian Cancer.

Journal: International journal of molecular sciences

Published: August 22, 2022

Letter to the editor: The clinically relevant MTARC1 p.Ala165Thr variant impacts neither the fold nor active site architecture of the human mARC1 protein.

Letter to the editor: The clinically relevant MTARC1 p.Ala165Thr variant impacts neither the fold nor active site architecture of the human mARC1 protein.

Journal: Hepatology communications

Published: April 14, 2022

Showing 1-12 of 61

Last Updated: 09/26/2026